Hong Kong Center for Clinical Research (HKCCR)
Speeding Up Clinical Trials

Hong Kong is a hub for biomedical research and home to a huge number of biomedical researchers. But most pharmaceutical and biotech companies conduct their research and clinical trials in universities, creating an opportunity gap for patients to participate in them.

Hong Kong Center for Clinical Research (HKCCR), the pioneering and largest clinical trial center in the private sector of Hong Kong, addresses this critical requirement and takes a prominent role in bridging this divide. It is a leading organization that conducts clinical trials in various areas, including bone diseases, degenerative diseases, metabolic diseases, nutrition, oncology, and ophthalmology.

“We act as a crucial link between the pharmaceutical and biotech industries and the patient community to speed up and market clinical trials,” says Dr. Edith Lau, Center Director of HKCCR.

Lau founded HKCCR 14 years ago, aiming to help pharmaceuticals fast-track clinical trials and market their products. It has a strong community network and diverse outreach activities allowing its team to reach a larger pool of patients compared to traditional hospital-based sites. Leveraging social media platforms, community events, and collaborations with patient societies, HKCCR successfully recruits a significant number of patients for clinical trials.

With the expertise in working with the ethics committee and regulatory authority, it can navigate the approval process swiftly and efficiently. It has also developed a robust referral network of healthcare professionals and research collaborators, enabling rapid patient recruitment and enrollment and ensuring successful completion of clinical trials.

HKCCR offers comprehensive on-site clinical services, providing patients with a convenient and streamlined experience during their participation in clinical trials.

The dedicated clinic, team and its partner vendors simplify sponsors’ work in setting up the site for their trials.

As Hong Kong positions itself as a scientific innovation hub, startup companies are developing innovative ideas for test kits, methods of diagnosis, nutritional products, drug molecules, and more. However, as most of these startups require more support in developing their products, HKCCR assists them in protocol writing, study start up application, and even conducting studies.

It also aids physicians in Hong Kong who are interested in conducting clinical trials in the private sector but lack the “know-how” or resources to initiate such studies. HKCCR helps them start their studies by providing site management services. Its team of coordinators collaborates with partner investigators to conduct studies in specific therapeutic areas, which requires specialized equipment, such as orthopedics, ophthalmology and oncology.

We act as a crucial link between the pharmaceutical and biotech industries and the patient community to speed up and market clinical trials

HKCCR has significantly contributed to the development of many transformative drugs, particularly in the areas of osteoporosis and osteoarthritis. Placing a strong emphasis on data quality, its team strictly adheres to good clinical practice (GCP) guidelines and implements a robust quality control system. This commitment guarantees the collected data’s accuracy and reliability, establishing a solid foundation for research outcomes and ensuring the credibility of the center’s findings.

HKCCR’s success can be attributed to its dedicated and well-trained research associates, who engage with patients in day-to-day operation. They have undergone rigorous GCP and internal training tailored to the center’s clinical trials. It emphasizes the importance of compassion and clear communication skills in its staff, with its patients receiving the utmost care and understanding throughout their participation in trials.

Striving to advance biomedical research and bridge patient-industry gaps, HKCCR has established itself as the preferred partner for accelerating medical innovations.